Neurocrine Biosciences (NBIX) is a biopharma company focused on treating CNS and endocrine disorders. Neurocrine has been cash flow positive for the last 2 years off the back of strong sales of Ingrezza, a soon-to-be blockbuster used to treat tardive dyskinesia. Rather than resting on its laurels, Neurocrine is reinvesting that cash flow to develop a broad pipeline of potential therapies that could meaningfully add to its upside over the next few years. Much like I described with Horizon Therapeutics, Neurocrine has a strong business model that gives me confidence that it